Breast Cancer Trial, Recruiting (NCT06197581)

Breast Cancer Trial, Recruiting NCT06197581 Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06197581 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 70 years old
You have been diagnosed with breast cancer confirmed by a tissue or cell test (biopsy or pathology)
Your overall health and ability to carry out daily activities falls within an acceptable range for this trial (confirm with trial site)
Your treatment plan includes radiation therapy to the chest wall or breast, with or without nearby lymph node areas
Your treatment plan also includes at least one of the following medicines: capecitabine, a CDK4/6 inhibitor, a PARP inhibitor, an immunotherapy drug (ICI), or a HER2-targeted therapy

Who may not be able to join:

You are male with breast cancer
You have had an allergic reaction to any of the medicines listed above in the past
Your treatment plan includes trastuzumab (a HER2-targeted drug) on its own, either during or after radiation therapy
You have another serious illness or medical condition (confirm with trial site for details on what qualifies)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Yirui Zhai, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phone: +86-10-87788058

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06197581

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase: Not Applicable

Status: Recruiting

Condition: Breast Cancer

Trial contact: +86-10-87788058

More information: https://clinicaltrials.gov/study/NCT06197581

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 70 years old
You have been diagnosed with breast cancer confirmed by a tissue or cell test (biopsy or pathology)
Your overall health and ability to carry out daily activities falls within an acceptable range for this trial (confirm with trial site)
Your treatment plan includes radiation therapy to the chest wall or breast, with or without nearby lymph node areas
Your treatment plan also includes at least one of the following medicines: capecitabine, a CDK4/6 inhibitor, a PARP inhibitor, an immunotherapy drug (ICI), or a HER2-targeted therapy

Who may not be able to join:

You are male with breast cancer
You have had an allergic reaction to any of the medicines listed above in the past
Your treatment plan includes trastuzumab (a HER2-targeted drug) on its own, either during or after radiation therapy
You have another serious illness or medical condition (confirm with trial site for details on what qualifies)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Registry

ClinicalTrials.gov

Start date

12 January 2024

Est. completion

15 January 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Grade 3 adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov